title: Comparison of three versions of Partin tables to predict final pathologic stage in a Chinese cohort: a decision curve analysis.
abstract: OBJECTIVE
  To compare Partin tables (PTs) 1997, 2001, and 2007 for their clinical applicability in a Chinese cohort based upon a decision curve analysis (DCA).
  
  
  METHODS
  Clinical and pathologic data of 264 consecutive Chinese patients with clinically localized prostate cancer were used. These patients underwent open radical prostatectomy between 2005 and 2011. DCA quantified the net benefit of different PT versions relating to specific threshold probabilities of established capsular penetration (ECP), seminal vesicle involvement (SVI), and lymph node involvement (LNI).
  
  
  RESULTS
  Overall, ECP, SVI, and LNI were recorded in 23.1, 10.2, and 6.1%, respectively. When the threshold probability was below the prevalence for LNI and ECP predictions, the DCA favored the 2007 version versus the 1997 version for SVI.
  
  
  CONCLUSIONS
  DCA indicates that for low threshold probability, decision models are useful to discriminate the performance differences of three PT versions, although net benefit differences were not apparent. For high threshold probability, there may not be an important benefit from the use of PTs and the current analysis cannot translate into meaningful net gains differences.
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Centre, China.
authors.forename: Wen-Jun
authors.initials: WJ
authors.lastname: Xiao
authors.forename: Ding-Wei
authors.initials: DW
authors.lastname: Ye
authors.forename: Xu-Dong
authors.initials: XD
authors.lastname: Yao
authors.forename: Shi-Lin
authors.initials: SL
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
mesh_terms: D000368:Aged; D002681:China; D015331:Cohort Studies; D020000:Decision Support Systems, Clinical; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D060787:Neoplasm Grading; D011336:Probability; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery*; D012669:Seminal Vesicles / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen